With $3.4-Million Investment, Invitrogen Will Market Illumina s Oligos and Split Revenues | GenomeWeb

Invitrogen will pay Illumina $3.4 million to manufacture oligonucleotides that it, in turn, will market, with the two companies splitting revenues 50-50, the companies said this week.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.